Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
The role of neuroimaging in Parkinson's disease
NSR Bidesi, I Vang Andersen… - Journal of …, 2021 - Wiley Online Library
Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
The present procedural guidelines summarize the current views of the EANM Neuro-
Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine …
Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine …
Distribution patterns of tau pathology in progressive supranuclear palsy
GG Kovacs, MJ Lukic, DJ Irwin, T Arzberger… - Acta …, 2020 - Springer
Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical
pathology in neurons, astrocytes, and oligodendroglia associated with various clinical …
pathology in neurons, astrocytes, and oligodendroglia associated with various clinical …
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
Purpose This joint practice guideline or procedure standard was developed collaboratively
by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear …
by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear …
Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis
Objective To systematically review and meta-analyse conversion rates from normal
cognition to Mild Cognitive Impairment (MCI) and dementia in Parkinson's disease (PD) …
cognition to Mild Cognitive Impairment (MCI) and dementia in Parkinson's disease (PD) …
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …
emphasises the need for consensus recommendations on the rational use of biomarkers to …
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases
Neurodegenerative diseases are a set of progressive and currently incurable diseases that
are primarily caused by neuron degeneration. Neurodegenerative diseases often lead to …
are primarily caused by neuron degeneration. Neurodegenerative diseases often lead to …
European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission …
Background and purpose Recommendations for using fluorodeoxyglucose positron
emission tomography (FDG‐PET) to support the diagnosis of dementing neurodegenerative …
emission tomography (FDG‐PET) to support the diagnosis of dementing neurodegenerative …
Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: still a valid option?
R Ferrando, A Damian - Frontiers in Neurology, 2021 - frontiersin.org
Biomarkers are playing a progressively leading role in both clinical practice and scientific
research in dementia. Although amyloid and tau biomarkers have gained ground in the …
research in dementia. Although amyloid and tau biomarkers have gained ground in the …